EGb 761 in the Syndrome of MCI With Concomitant CVD
Evaluating the Role of EGb 761 in the Syndrome of Mild Cognitive Impairment With Concomitant Cerebrovascular Disease (MCI + CVD)
National Neuroscience Institute
134 participants
Oct 26, 2020
INTERVENTIONAL
Conditions
Summary
EGb 761 has been demonstrated to be useful in improving cognitive and global clinical outcomes in patients with cognitive impairment or dementia, when administered at a daily dosage of 240mg in randomised controlled trials through several neuroprotective mechanisms of action. The study aims to determine the efficacy and safety profile of EGb 761 as a prescribed clinical drug for patients with MCI + CVD.
Eligibility
Inclusion Criteria6
- Patients who have been diagnosed with MCI based on the Petersen criteria and Albert MS criteria
- Patients who have a Global Clinical Dementia Rating Score of 0.5
- Patients aged 45 to 85 years at study entry
- Patients who are literate and able to complete the cognitive evaluations in the opinion of the investigators
- Patients with the presence of CVD, defined as the presence of white matter hyperintensities (WMH) of Fazekas grade 2 or 3 on MRI brain imaging (done up to 12 months prior to recruitment) or CT scans for patients contraindicated from MRI scans
- Patients who provide written informed consent to participate in the study
Exclusion Criteria1
- Participants should not be receiving antidepressants, antipsychotics, benzodiazepines, acetylcholinesterase inhibitors or NMDA antagonists during the study. Additionally, contraindications for EGb 761 as given in the local prescribing information/Summary of Product Characteristics (SmPC) should be observed.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Dietary supplement: Gingko biloba EGb 761
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04525144